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The previous pharmacokinetic methods can be only limited to drug analysis in vitro, which provide less
information on the distribution and metabolismof drugs, and limit the interpretation and assessment of
pharmacokinetics, the determination of metabolic principles, and evaluation of treatment effect. The
objective of the study was to investigate the pharmacokinetic characteristics of gene recombination
angiogenesis inhibitor Kringle 5 in vivo. The SPECT/CT and speciﬁc 131I-Kringle 5 marked by Iodogen
method were both applied to explore the pharmacokinetic characteristics of 131I-Kringle 5 in vivo, and to
investigate the dynamic distributions of 131I-Kringle 5 in target organs. Labeling recombinant angio-
genesis inhibitor Kringle 5 using 131I with longer half-life and imaging in vivo using SPECT instead of PET,
could overcome the limitations of previous methods. When the doses of 131I-Kringle 5 were 10.0, 7.5 and
5.0 g/kg, respectively, the two-compartment open models can be determined within all the metabolic
process in vivo. There were no signiﬁcant differences in t1/2α, t1/2β, apparent volume of distribution and
CL between those three levels. The ratio of AUC(01) among three different groups of 10.0, 7.5 and 5.0 g/
kg was 2.56:1.44:1.0, which was close to the ratio (2:1.5:1.0). It could be clear that in the range of 5.0–
10.0 g/kg, Kringle 5 was characterized by the ﬁrst-order pharmacokinetics. Approximately 30 min after
131I-Kringle 5 was injected, 131I-Kringle 5 could be observed to concentrate in the heart, kidneys, liver and
other organs by means of planar imaging and tomography. After 1 h of being injected, more radionuclide
retained in the bladder, but not in intestinal. It could be concluded that 131I-Kringle 5 is mainly excreted
through the kidneys. About 2 h after the injection of 131I-Kringle 5, the radionuclide in the heart, kidneys,
liver and other organs was gradually reduced, while more radionuclide was concentrated in the bladder.
The radionuclide was completely metabolized within 24 h, and the distribution of radioactivity in rats
was similar to normal levels. In our study, the speciﬁc marker 131I-Kringle 5 and SPECT/CT were suc-
cessfully used to explore pharmacokinetic characteristics of Kringle 5 in rats. The study could provide a
new evaluation platform of the speciﬁc, in vivo and real-time functional imaging and pharmacokinetics
for the clinical application of 131I-Kringle 5.
& 2016 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Drug metabolism pharmacokinetics was the research on ab-
sorption, distribution, metabolism and excretion of the drug
in vivo, namely called ADME. At present, ADME had a develop-
ment trend of diversiﬁcation and reﬁnement. The commonly re-
search methods included spectrophotometry, chromatography,
immunoassays, biological analysis and isotope labeling. However,
due to the biological variations, large measurement error, pooron and hosting by Elsevier B.V. Th
University.reproducibility and more confounders, bioassay was only the
supplement of physical and chemical test. Based on speciﬁc anti-
gen-antibody reaction, immunization was characterized by high
sensitivity, fast operation and high-throughput assay [1]. Con-
sidering the complex sampling process, incontinuity of observa-
tion, and large sample size, the methods above mentioned were
unsuited to drug metabolism studies in vivo. The previous phar-
macokinetic methods could be only conﬁned to drug analysis in
vitro, which provided less information on the distribution and
metabolismof drugs, and limit the interpretation and assessment
of pharmacokinetics, the determination of metabolic principles,
and evaluation of treatment effect [2].
Isotope tracer method is the trace analysis in which radio-
nuclides serve as tracers to mark [3]. Compared with theis is an open access article under the CC BY-NC-ND license
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vantages of high sensitivity, simple operation, more accuracy, less
confounders and errors of separation and puriﬁcation. Radi-
olabelled tracer technology could be used not only to observe the
absorption, distribution, metabolism and excretion of drugs, but
also to locate drugs by imaging, and orient cell and organelles
using light microscopy and electron microscopy [5–11]. To better
investigate the distribution of drugs in vivo, Bergstrom et al. [12]
ﬁrst used positron emission tomography (PET) in pharmacokinetic
study. Since the half-life period of markers 11C and 18F of PET is so
short (about 20 min and 110 min), it is difﬁcult to analyze drug
distribution in the body through special routes [13]. Because of
less compatibility and more complexity, PET radioactive labeling is
difﬁcult to popularize in a short time [14–16]. In this study, we
used 131I with longer half-life to label recombinant angiogenesis
inhibitor Kringle 5 and SPECT instead of PET to image in vivo,
which could overcome the limitations of previous methods.2. Materials and methods
2.1. Instruments
SPECT/CT Imaging System was Inﬁnia VC Hawkeye4 from GE
Company Milwaukee (Wisconsin, USA). DFM296 multi-tube
radioimmunoassay counter and γ scintillation counter were made
in 262 Factory in Xi'an of China. Sephadex G-25 column was from
Pharmacia Corporation (Stockholm, Sweden).
2.2. Targeted drugs
Recombinant angiogenesis inhibitor Kringle 5 was white lyo-
philized powder, split charging 30 mg in vials. The batch number
was 20110402; they were provided by Professor Liujiao Bian in
National Micro Detection System Engineering Research Center in
Northwestern University, China and freshly prepared before test-
ing every time. Lodogen (tetrachloro-diphenyl glycoluril) was from
Sigma Company in San Francisco of USA and was used for iodine-
labeled-solid-phase oxidant. Fetal bovine serum was obtained
from GIBCO Company (New York, USA).
2.3. 131I labeled Kringle 5 using Iodogen method [17–20]
2.3.1. Smear
First of all, 0.5 mg Iodogen was weighed by electronic precision
balance and dissolved in 0.25 mL organic solvent of chloroform.
Then, 30 μL of solution acquired above (containing approximately
50 μg Iodogen) was taken to pack in the experimental EP tube and
normally dry at 4 °C. Finally, it was smeared evenly the bottom of
the experimental tube with Iodogen, sealed and cryopreserved at
20 °C for application.
2.3.2. Label
20 μg/20 μL Kringle 5, 500 μCi/10 μL Na131I and 100 μL PBS
were mixed. Their action remained approximately 20 min in EP
tube, and then the tube was gently shaked. At last, the mixed
solution was transferred out of experimental tube and the reaction
was stopped. The steps above should be repeated three times.
2.3.3. Puriﬁcation
In order to avoid albumin iodization in the column of buffer
solution, we will keep 5 min to revert unlabeled iodide ions to
molecular iodine before chromatography separation. The whole
reaction solution was added into Sephadex G-25 gel to ﬁlter, and
then eluted with 0.05 M (pH7.5) phosphate buffer at a ﬂow rate of
0.5 mL/min and 1 cm above the column side. A total of 16 tubeswere collected at the speed of one/min, and numbered all of them;
meanwhile, radiation count per minute (CPM) of each tube was
measured and mark rate was calculated. In the end, these tubes
were sealed and cryopreserved at 20 °C.
2.3.4. Separation
At the bottom of ﬁlter paper, 131I- Kringle 5 solution was
dripped rapidly by the capillary, and ammonium hydroxide served
as developing solvent. 10 μL eluent in each tube was also taken.
The γ scintillation counter was used to count in 10 s. The elution
curve was drawn in graph paper, where the ﬁrst peak was the
protein vertex, and the second peak was free iodine vertex or
impurity vertex. We further collected protein vertex, diluted it
with normal saline, and identiﬁed the product. The experiment
procedures above should be repeated three times.
2.3.5. Identiﬁcation
The appropriate amount of eluent of protein peaks was dripped
on the paper (What man 1#), and chromatographically spread
upwards in n-butanol: ethanol: aqueous ammonia system (5:1:2,
v/v/v), which was divided into 10 sections. Next, we counted with
γ scintillation counter at channel energy 364 keV, and calculated
radiochemical purity (radio-chemical purity, RP).
2.4. Pharmacokinetics of speciﬁc labeled 131I-Kringle 5 in vivo [21,22]
Eighteen SD rats, with weight 200–220 g, half of who were
female, were divided into three groups of different doses (Medi-
cine Laboratory Animal Center of Xi'an Jiaotong University; the
production license number: SCXK (Shaanxi) 2012-003, usage li-
cense number: SYXK (Shaanxi) 2012-005).131I-Kringle 5 in 2 μg
(4μCi) was injected into femoral vein of every rat. After 0.25, 0.5,
0.75, 1, 1.5, 2, 4, 6, 8, 12, 24 h respectively of being injected, 0.2 mL
blood sample was drawn from rear eye venous plexus of these rats,
and EDTA anticoagulant was also required. The blood samples
were centrifugalized at 3000 r/min for 10 min at 4 °C. In the next
step, we took 100 μL separate plasma and directly measured
radioactivity counts with DFM296 multi-tube radioimmunoassay
counter. The corresponding plasma concentration was calculated
according to the following formula: plasma concentration
(μg/mL)¼[measured radiation counts (CPM)2 μg]/[injected
dose radiation counts (CPM)0.1 mL].
2.5. The imaging distribution of radionuclide-labeled 131I-Kringle
5 in vivo
After 0.5, 1, 2, 6, 24 h of injecting 131I-Kringle 5 into sublingual
vein of 5 rats, SPECT system (Inﬁnia Hawkeye 4, GE) with high-en-
ergy collimators, energy window 360 keV, andmagniﬁcation 5 times,
the acquisition count 50 counts, was used to obtain planar imaging.
Three-dimensional tomography of SPECT/CT combined with image
fusion using speciﬁc software, was further used to obtain anatomical
and functional imaging and fusion imaging in real time.3. Results
3.1. The labeled rate of 131I-Kringle 5
The labeled rate of 131I-Kringle 5 was approximately 84.6% in
this study. Bimodal curve is shown in Fig. 1.
3.2. The concentration of 131I-Kringle 5 in blood within different time
points
After 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 24 h of injecting
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centration of 131I-Kringle 5 in blood is shown in Table 1.
3.3. The pharmacokinetic parameters of 131I-Kringle 5 in vivo
We draw a curve of the relationship between time and the
concentration of Kringle 5 in blood of rats using software DAS 2.0.
When the doses of Kringle 5 were 10.0, 7.5 and 5.0 g/kg respec-
tively, the results showed that the metabolic process of Kringle
5 in rats was consistent with a two-compartment model. The ratio
of AUC (0 1) between the three groups was 2.56:1.44:1.0, which
was similar to the ratio (2:1.5:1.0) of the three groups. It is con-
cluded that the ﬁrst-order kinetics metabolism of Kringle 5 could
be found in the study when the doses ranged from 5.0 to 10.0 g/kg
(Table 2).
3.4. The imaging distribution of radionuclide-labeled 131I-Kringle
5 in vivo
After 0.5, 1, 2, 6, 24 h of injecting 131I-Kringle 5 into sublingualFig. 1. The curve of labeled rate of 131I-Kringle 5.
Table 1
The concentration of 131I-Kringle 5 in blood within different time periods across
different dose groups.
The time of taking
blood (h)
Concentration of 131I-Kringle 5 (g/L)
10.0 g/kg 7.5 g/kg 5.0 g/kg
0.25 0.146770.0124 0.102770.0080 0.056370.0193
0.5 0.143270.0185 0.090770.0098 0.047770.02096
0.75 0.133070.0186 0.086770.0152 0.048170.0121
1.0 0.127670.0367 0.078070.0067 0.046970.0116
1.5 0.115870.0139 0.068470.0145 0.039070.0099
2.0 0.106170.0253 0.063670.0125 0.038170.01340
4.0 0.103970.0218 0.051470.0076 0.034070.0108
6.0 0.083170.0163 0.048670.0092 0.028470.0048
8.0 0.080970.0162 0.041670.0119 0.026170.0071
12.0 0.047170.0071 0.029570.0074 0.019070.0038
24.0 0.035870.0085 0.020670.0042 0.0149770.0021
Table 2
The pharmacokinetic parameters of compartment model of 131I-Kringle 5.
AV parameters The doses of 131I-Kringle 5 (g/kg)
10.0 7.5 5.0
t1/2α (h) 0.48470.280 0.71770.324 0.64270.24
t1/2β (h) 14.13472.426 15.26374.093 17.61275.292
V1(L/kg) 60.23878.896 64.18274.005 76.504732.383
CL (L/h/kg) 4.48471.043 5.86670.895 5.70771.176
AUC(0t)(μg/L h) 1.60970.190 0.92870.143 0.57370.113
AUC(0-1) (μg/L h) 2.32570.513 1.30470.196 0.90570.186
Fig. 2. The imaging of radionuclide distribution at 0.5 h after injection of 131I-
Kringle 5.
Fig. 3. The imaging of radionuclide distribution at 1 h after injection of 131I-Kringle 5.vein of rats, functional imaging and real-time fusion imaging using
SPECT were obtained. After 30 min, it was clear that 131I-Kringle
5 had concentrated in the heart, kidneys, liver and so on (Fig. 2).
After 1 h, there was more radionuclide accumulated in the bladder,
but not found in the intestinal (Fig. 3). After 2 h, the concentration
of radionuclide in the heart, kidneys and liver were increasingly
reduced, while more radionuclide was concentrated in the bladder
(Fig. 4). After 6 h, the level of radionuclide in the heart, kidneys,
liver and other parts continued to reduce, and no radionuclide
could concentrate in the bladder. The distribution of radioactivity
in vivo was close to normal background level (Fig. 5). After 24 h,
the levels of radioactivity in the heart, kidney and liver had ap-
proximated to normal background level. There was not any
Fig. 4. The imaging of radionuclide distribution at 2 h after injection of 131I-Kringle
5.
Fig. 5. The imaging of radionuclide distribution at 6 h after injection of 131I-Kringle
5.
Fig. 6. The imaging of radionuclide distribution at 24 h after injection of 131I-
Kringle 5.
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suggested that 131I-Kringle 5 was mainly excreted by the kidneys.
About 2 h after the injection of 131I-Kringle 5, the level of radio-
nuclide gradually decreased in the heart, kidneys and liver, while
an amount of radionuclide was concentrated in the bladder. The
radionuclide in vivo was completely metabolic away within 24 h,
and reached normal levels.4. Discussion
In the process of tumor growth and metastasis, recent studies
have indicated that there is sustained and uncontrolled angio-
genesis, which plays an important role in tumor growth, invasion
and metastasis. It is also found that angiogenesis is a complexprocess, which includes activation, proliferation and migration of
endothelial cell, and damage of vascular basement membrane, and
the formation of new blood vessels and vascular network, and
connection to the existent vascular. It further proves that angio-
genesis is required for further growth of the 1–2 mm tumor;
otherwise it could not continue to grow [23]. The latest research
shows that Kringle 5 has a strong inhibiting effect on the angio-
genesis and growth of tumor [24]. However, the distribution and
metabolic characteristics of Kringle 5 in the body have not been
found yet so far.
In the study, by using SPECT imaging system and SPECT/CT
three dimensional tomographic fusion imaging, we obtained
anatomical and functional imaging and real-time fusion imaging,
and continuously and dynamically observed the absorption, dis-
tribution and excretion of recombinant angiogenesis inhibitor 131I-
labeled Kringle 5 in vivo.
131I is one of the most common radioisotopes for labeling, but
there must be a perssad combined with iodine atom in the interior
of marked compound. In other words, it must contain casein or
histamine amine residues [17]. As protein lysates of human plas-
minogen fragment that could speciﬁcally prohibit the proliferation
of vascular endothelium, Kringle 5 having a strong anti-angiogenic
effect is a potential anticancer drug [23]. It can meet the basic
requirements for radioactive iodine-labeled, because its amino
acid residue contains casein group at site 64, 72, 74, being far from
the active site [24]. Yin et al. [25] proved that Indogen labeling
method had not any impacts on biological activity and distribution
of Kringle 5 in vivo. In the meanwhile, SPECT is considered to a
good way of imaging that could present the distribution of labeled
drug in vivo. Both comprehensively applications of Indogen la-
beling and SPECT could not only reﬂect the biological processes of
Kringle 5 in vivo, but also increase the experimental sample size.
Moreover, there were higher sensitivity and feasibility compared
to other non-isotopic labeling methods. Therefore, a combination
of Indogen isotope labeling and SPECT technique is an excellent
approach for the pharmacokinetic study of Kringle 5.
In this study, after 131I-Kringle 5 was injected into the sub-
lingual vein of rats, the transport rate of the drug in vivo was in
accordance with open two-compartment model, that was the
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layed to some extent. It showed that Kringle 5 conducts a ﬁrst-
order kinetics metabolism in the dose range of 5.0–10.0 g/kg.
The results of 131I-Kringle 5 pharmaceutical kinetic from SPECT/
CT tomographic image showed that 131I-Kringle 5 was absorbed
quickly after injection and clearance quickly from the blood pool
and ﬁnally most of the131I-Kringle 5 was concentrated in the
bladder. This result suggested that 131I-Kringle 5 was mainly ex-
creted through the urinary system, which was difference from the
other traditional 131I labeled compounds such as 131I-AFP mono-
clonal antibody which was mainly excreted through the hepatic
system. These metabolic characteristics is more helps to clinic
observation of 131I-Kringle 5 concentration in vivo because urinary
system clearance is more quickly than the hepatic system, which
provides more clear SPECT/CT tomographic image contrast.
The ﬁnal results in this experiment revealed that it was feasible
technologically to label recombinant angiogenesis inhibitor Krin-
gle 5 with radioactive 131I. The pharmacokinetic data on 131I-
Kringle 5 in rats provided scientiﬁc basis for further clinical ap-
plication. In the pharmacokinetic study of Kringle 5 in rats, we also
used angiogenesis inhibitor Kringle 5 to explore speciﬁc target
organs and metabolic level using speciﬁc markers. The pharma-
cokinetic study of speciﬁcally labeled Kringle 5 in vivo using SPECT
imaging system also provided imaging basis of the drug metabo-
lism. The successful application of speciﬁc Iodogen labeling
method was important to study pharmacokinetics of angiogenesis
inhibitor Kringle 5 in vivo, and provided a new approach for
pharmacokinetic study.
This study established pharmacokinetic method of Kringle
5 in vivo, based on the speciﬁc Iodogen labeling method and
SPECT/CT imaging system. The pharmacokinetic status of re-
combinant angiogenesis inhibitor Kringle 5 in live animals had
been clearly shown in this study, which overcome the limitations
of previous methods that were subject to changes of blood con-
centration and organ pathology after administration [23]. Ac-
cording to metabolic level of angiogenesis inhibitor Kringle 5 in
speciﬁc target organs of live animals, we analyzed the inhibiting
effect of Kringle 5 on vascular growth, and then further in-
vestigated similar effect on tumor growth [26]. It is expected that
the study could provide important basis for inhibiting tumor
growth.
The differences between this study and other previous studies
are also presented as follows. In our study, the same experimental
rats were monitored dynamically in different experimental peri-
ods, which ensure the consistency of the experimental conditions,
eliminates individual variations, and keeps the accuracy of results.
Especially, as optimizing the program, we also made sure “3Rs”
welfare of animals [27]. Through dynamically monitoring the same
experimental rats in vivo among different administration time in
the experiment, which altered traditional program of observation
after being killed, it could greatly reduce sample size of laboratory
animals. In other words, this is a cost-effective scientiﬁc method
which uses the relatively small samples to get more experimental
data. There were strictly operated and guided programs for the
staff during the experiment. When keeping the animal completely
under anesthesia during the experiment, we endeavor to alleviate
the suffering of rats to the maximum extent and provide huma-
nistic concern. Throughout this study, we continuously improve
experiment protocol, to avoid and reduce pain and anxiety of ex-
perimental animals, to ensure the reliability of the results. The
whole experimental program included “3Rs” welfare of experi-
mental animals, respects for life of them and compliances the
ethical principles of experimental animals.In summary, the applications of speciﬁc labeling 131I-Kringle
5 and functional imaging of SPECT/CT establishes pharmacokinetic
method of Kringle 5 in rats, and provides the new platform of real-
time pharmacokinetic functional imaging in vivo.References
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